BioLife Solutions, Inc. Payments to Acquire Debt Securities, Available-for-sale
BioLife Solutions, Inc. (BLFS) reported Payments to Acquire Debt Securities, Available-for-sale of $35.35 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-06
- BioLife Solutions, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $14.93M, a 56.08% decline year-over-year.
- BioLife Solutions, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $20.43M, a 32.63% decline year-over-year.
- BioLife Solutions, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $36.67M, a 1427.28% increase year-over-year.
- BioLife Solutions, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $13.09M, a 146.89% increase year-over-year.
- BioLife Solutions, Inc. payments to acquire debt securities, available-for-sale for fiscal 2025 was $114.06M, a 519.40% increase from fiscal 2024.
- BioLife Solutions, Inc. payments to acquire debt securities, available-for-sale for fiscal 2024 was $18.41M, a 32.04% decline from fiscal 2023.
- BioLife Solutions, Inc. payments to acquire debt securities, available-for-sale for fiscal 2023 was $27.09M, a 48.99% decline from fiscal 2022.
- BioLife Solutions, Inc. payments to acquire debt securities, available-for-sale for fiscal 2022 was $53.12M.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $14.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $35.35M 10-Q · filed 2026-08-06 | $72.03M derived: sum of 3 quarters · filed 2026-08-06 | $85.11M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $20.43M 10-Q · filed 2026-05-07 | $57.10M derived: sum of 2 quarters · filed 2026-05-07 | $70.19M derived: sum of 3 quarters · filed 2026-05-07 | $104.17M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $36.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $49.76M derived: sum of 2 quarters · filed 2026-02-26 | $83.74M derived: sum of 3 quarters · filed 2026-08-06 | $114.06M 10-K · filed 2026-02-26 |
| 2025-09-30 | $13.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $47.07M derived: sum of 2 quarters · filed 2026-08-06 | $77.39M 10-Q · filed 2025-11-06 | $79.79M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $33.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $64.30M 10-Q · filed 2026-08-06 | $66.70M derived: sum of 3 quarters · filed 2026-08-06 | $72.01M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $30.32M 10-Q · filed 2026-05-07 | $32.73M derived: sum of 2 quarters · filed 2026-05-07 | $38.03M derived: sum of 3 quarters · filed 2026-05-07 | $42.37M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $2.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $7.70M derived: sum of 2 quarters · filed 2026-02-26 | $12.04M derived: sum of 3 quarters · filed 2026-02-26 | $18.41M 10-K · filed 2026-02-26 |
| 2024-09-30 | $5.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $9.64M derived: sum of 2 quarters · filed 2025-11-06 | $16.01M 10-Q · filed 2025-11-06 | $20.42M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $4.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $10.71M 10-Q · filed 2025-08-07 | $15.12M derived: sum of 3 quarters · filed 2026-02-26 | $22.08M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $6.37M 10-Q · filed 2025-05-08 | $10.78M derived: sum of 2 quarters · filed 2026-02-26 | $17.74M derived: sum of 3 quarters · filed 2026-02-26 | $25.27M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $4.41M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $11.37M derived: sum of 2 quarters · filed 2026-02-26 | $18.89M derived: sum of 3 quarters · filed 2026-02-26 | $27.09M 10-K · filed 2026-02-26 |
| 2023-09-30 | $6.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $14.49M derived: sum of 2 quarters · filed 2024-11-12 | $22.69M 10-Q · filed 2024-11-12 | $40.04M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $7.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $15.73M 10-Q · filed 2024-08-09 | $33.08M derived: sum of 3 quarters · filed 2025-03-03 | $45.77M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $8.20M 10-Q · filed 2024-05-10 | $25.55M derived: sum of 2 quarters · filed 2025-03-03 | $38.24M derived: sum of 3 quarters · filed 2025-03-03 | |
| 2022-12-31 | $17.35M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $30.04M derived: sum of 2 quarters · filed 2025-03-03 | $53.12M 10-K · filed 2025-03-03 | |
| 2022-09-30 | $12.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $35.77M 10-Q · filed 2022-11-09 | ||
| 2022-06-30 | $23.07M 10-Q · filed 2022-08-09 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $0.00 derived: sum of 2 quarters · filed 2024-02-29 | $0.00 10-K · filed 2024-02-29 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $0.00 10-Q · filed 2022-11-09 | ||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-09 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Axogen, Inc. (AXGN) | United States | $2.329B | -73.83 |
| CONMED Corp (CNMD) | United States | $1.353B | 26.72 |
| Ceribell, Inc. (CBLL) | United States | $0.916B | -11.27 |
| TransMedics Group, Inc. (TMDX) | United States | $2.911B | 15.17 |
| CapsoVision, Inc (CV) | United States | $0.310B | -12.68 |
| Electromed, Inc. (ELMD) | United States | $0.233B | 31.13 |
| EDAP TMS SA (FOCL) | $0.171B | ||
| Stereotaxis, Inc. (STXS) | United States | $0.130B | -7.53 |
| Vivani Medical, Inc. (VANI) | United States | $0.111B | |
| electroCore, Inc. (ECOR) | United States | $0.102B |